02:12 PM EDT, 09/15/2025 (MT Newswires) -- (Updates with recent share movement in headline and first paragraph.)

ATyr Pharma ( ATYR ) shares were down 82% in recent Monday trading after the company reported that a phase 3 study of efzofitimod to treat pulmonary sarcoidosis, a type of lung disease, missed its primary endpoint.

The study's primary endpoint was the change from baseline in mean daily oral corticosteroid dose at week 48.

The biotech company said it will seek a review of the results with the US Food and Drug Administration to "determine the path forward for efzofitimod in pulmonary sarcoidosis."

Price: 1.06, Change: -4.97, Percent Change: -82.42